Kalil Abdullah, System Director of CNS Cancer at Northwell Health, shared on LinkedIn:
“Since the FDA approval of vorasidenib to treat IDH mutant glioma, we’ve wanted more information on what happens biologically when patients are treated with an IDH inhibitor, then chemotherapy and radiation. This week in Science Translational Medicine in a study led by the amazing Diana Shi, we showed that mice who were treated with vorasidenib followed by chemoradiation did better than those with chemoradiation alone. The study also included a cohort of patients with similar characteristics.
Proud to be a part of impactful translational science with this fantastic group of scientists and physicians from across the globe.”
Title: Vorasidenib improves response to subsequent chemoradiation in a genetically engineered mouse model of IDH-mutant glioma
Authors: Diana D. Shi, Ester Calvo Fernández, Vinesh T. Puliyappadamba, Tyler A. Lanman, Yi Xiao, Zebin Wen, Maria Minor, Diego Prost, Aleksandra B. Lasica, Feng Cai, Ethan Neumann, Sriram Gudipelly, Louise M. Clark, Quang-De Nguyen, Salvador Peña, Janaka Wansapura, Pranita Kaphle, Tracey Shipman, Michael M. Levitt, Mathew D. Lin, Alexander C.-Y. Tsai, Joyce H. Lee, Daniel P. Cahill, Rifaquat Rahman, Daphne A. Haas-Kogan, Timothy E. Richardson, Itay Tirosh, Payal Jain, Adriana E. Tron, Vihang Nakhate, Gilbert Youssef, Caroline Dehais, Julian Jacob, David A. Reardon, Julie J. Miller, Kalil G. Abdullah, Patrick Y. Wen, Ralph J. DeBerardinis, Lin Xu, Mehdi Touat, Katherine B. Peters, L. Nicolas Gonzalez Castro, William G. Kaelin, Jr, Mario L. Suvà, Samuel K. McBrayer.
Read the full article.
To which Simon Khagi, Founder at SKBio Advisory, added:
“An important proof of concept and evidence for mechanism for IDH inhibition BEFORE chemotherapy and radiation. We need to continue to push out chemo/radiation as far as possible in the appropriate patient population. This is how we advance the field. Thanks for bringing this to light, Kalil Abdullah.”
You might be interested in:
Vorasidenib Approved in the UK: New Treatment for IDH1/2-Mutant Low-Grade Gliomas
